[1] Raine T, et al. ECCO Guidelines on Therapeutics in UC: MedicalTreatment. J Crohns Colitis.2022;16(1):2-17.

[2] Torres J, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: medical treatment. J Crohns Colitis.2019;jjz180.

[3] Kucharzik T, et al. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in IBD. J Crohns Colitis. 2021;15(6):879-913.

[4] Feuerstein JD, et al. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in IBD. Gastroenterology. 2017;153(3):827-34.

[5] Amiot A, et al. Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus, Digestive and Liver Disease 2021;53(1):35-43.

[6] Kirchgesner J. Risk of Serious and Opportunistic Infections Associated With Treatment of IBD. Gastroenterology. 2018;155(2):337-46.e10.

[7] TurnerD, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in IBD (STRIDE) IOIBD: Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570-83.

[8] Al Khoury A, et al. Patient Perspectives and Expectations in IBD: A Systematic Review. Dig Dis Sci [Internet]. 2021 [cité 8 févr 2022]; https://link.springer.com/10.1007/s10620-021-07025-y.

[9] Farraye FA, et al. ACG Clinical Guideline: Preventive Care in IBD. Am J Gastroenterol. 2017;112(2):241-58.

[10] Maaser C, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis.2019;13(2):144-64K.

[11] Doherty G, et al. ECCO Topical Review on Treatment Withdrawal [‘Exit Strategies’] in IBD.J Crohns Colitis. 2018;12(1):17-31.